Skip to content

Revvity, Inc. (RVTY) Company Overview

Company Analysis

Revvity, Inc. RVTY

A comprehensive view of key metrics, scores, and financial health for Revvity, Inc.

Overview of Revvity, Inc.

RVTY NYQ
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Large Cap
Revvity, Inc. (RVTY), is a Large Cap company, in the Diagnostics & Research industry, last closed at $151.60, about 72.7% overvalued vs fair value, +69.3% 1Y return, ranked 502/1145 in sector.
Metrics P/E 46.8× Rev Growth 3.7% ROE 3.2% Gross Margin 54.8% Div Yield 0.30%
USD 151.60
-3.44%
(Delayed)
• Vol 90d: 35.7%
52-Week Range
Market Cap
$16.92B
Enterprise Value
$19.10B
Overall Score
Overall
Growth
Weak
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Fair
Growth
Weak
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Fair
Completeness: 100%
Confidence: 98%
Updated: Oct 31
Top Beats

Quick Facts

HQ Waltham, MA
Employees 11,000
Fiscal year Dec 31

Next Events

Dividend Nov 13

Fair Value Snapshot

Bear Base Bull
$37
$41
$47
Current: $151.60 -73% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$2.9B
3.7%%
Gross Profit
$1.6B
1.7%%
Operating Income (GAAP)
$356.6M
2.9%%
EBITDA
$765.8M
-8.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
54.8%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$853.6M
167.6% of Free Cash Flow

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
4/4
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Revvity, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
68
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Key strengths

  • Strong FCF Generation FCF margin quality is top-tier vs peers (score 0.85). High FCF conversion confirms strong earnings quality.
  • Strong Operating Margin vs Peers Operating margin level is strong vs peers (score 0.79). SG&A discipline is converting gross margin into operating profit efficiently.

Key risks

  • Elevated Leverage Leverage is elevated vs peers (score 0.32). High net debt/EBITDA limits the balance sheet's acquisition firepower.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
59

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing RVTY's balance between Growth (19.7%), Profitability (46.7%), and Safety (33.6%). Growth 20% Safety 34% Profitability 47%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

30th percentile vs peers
31
Key Signals
Rev Growth YoY 3.7% 40p EPS Growth YoY -6.0% 27p TSR -13.1% 43p Revenue CAGR 3Y -4.8% 20p EPS CAGR 3Y -22.8% 16p
  • FCF Margin in top 20% of peers (17.8%, 91th percentile)
  • Operating Margin in top 20% of peers (12.5%, 81th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Operating Cash Flow Margin in top 20% of peers (20.4%, 84th percentile)
  • Growth below peer median (percentile: 30)

Profitability

73th percentile vs peers
73
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

52th percentile vs peers
53
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Revvity, Inc..

Loading scenario defaults...
Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$41.38
- - -
-72.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000